Article
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
Clinical genitourinary cancer - 1 Feb 2015
Jardim Denis L F, de Melo Gagliato Débora, Falchook Gerald, Zinner Ralph, Wheler Jennifer J, Janku Filip, Subbiah Vivek, Piha-Paul Sarina A, Fu Siqing, Tannir Nizar, Corn Paul, Tang Chad, Hess Kenneth, Roy-Chowdhuri Sinchita, Kurzrock Razelle, Meric-Bernstam Funda, Hong David S
Abstract excerpt
BACKGROUND: The purpose of this study was to determine the prevalence of MET amplification and mutation among GU malignancies and its association with clinical factors and responses to c-MET inhibitors. PATIENTS AND METHODS: Patients with GU malignancies referred to our Phase I Clinical Trials Program were evaluated for MET mutation and amplification and outcomes using protocols with c-MET inhibitors. RESULTS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.